Our Centre for Therapeutics Discovery puts targets on the road to the clinic
Does your organisation have a portfolio of potential drug targets? We could collaborate with you on a small molecule drug discovery or therapeutic antibody project. All risks are shared, and we discuss all commercialisation routes. To find out more and discuss how we could work together, please Contact Us.
How we translate targets into small molecule drugs
For small molecule drug discovery projects we develop assays, conduct screening campaigns, and engage in medicinal chemistry programmes.
We collaborate with MRC and non-MRC scientists and clinicians, many of whom are world leaders in their field. Our medicinal chemistry teams have more than 100 people years of pharmaceutical industry experience. We can deliver potent and selective lead compounds with efficacy in relevant disease models.
How we deliver humanized antibodies
Our Therapeutic Antibody Group, with over 20 years of experience working with both industry and academic groups, uses its substantial antibody engineering know-how to target major life threatening and debilitating diseases.
Antibody humanization is a rapid and reliable process which offers short clinical development times, high regulatory approval rates and good management of risk. Antibody humanization is a clinically validated technology, with 13 antibodies already on the market (of which 2, Tysabri® and Actemra®, were humanized by our group) and a further 100 or more in clinical trials.